Olga Borisovna Melashchenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olga Borisovna Melashchenko has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Victor Ivanovich Seledtsov
Institute for Fundamental and Clinical Immunology, 630099 Novosibirsk, Russia
9 shared publications - Vladimir Vladimirovich Malashchenko
Center for Immunology and Cellular Biotechnology, Immanuel Kant Baltic Federal University, 236001, Kaliningrad, Russia
9 shared publications - Natalia Dinislamovna Gazatova
Immanuel Kant Baltic Federal University
8 shared publications - Andrei Gennadievich Goncharov
Immanuel Kant Baltic Federal University
6 shared publications - Viacheslav Anatolievich Shmarov
Institute of Biomedical Problems, Russian Academy of Sciences (IBMP RAS), Moscow 123007, Russia
5 shared publications - Natalia Mikhailovna Todosenko
Immanuel Kant Baltic Federal University
4 shared publications
Latest Publications
- Open Access
- 28 September 2025
- Published by Russian Society of Immunology in Russian Journal of Immunology
- Vol. 28 (4) , 931-938
Content of RANTES, IL-8 and MIP-1β chemokines in platelet lysates obtained from donor blood
Growth supplements obtained from animal sera have a rather variable range of a specific growth factor contents and are subject to potential contamination. Moreover, the growth supplements obtained from animal raw materials contain a composition of proteins, vitamins and microelements necessary for full-fledged cell growth, and one may overcome these drawbacks by replacing them with a product obtained from human donor blood. Platelet lysate contains biologically active molecules derived from endogenous granules of these blood elements. Concentration of distinct biocomponents in the resulting product is variable, depending not only on gender and blood group, but also on other, as yet unidentified individual characteristics. The aim of this study was to examine the content of some chemokines, in particular, RANTES, MIP-1β and IL-8, in platelet lysates obtained from healthy donors. The highest concentrations of MIP-1β cytokine were noted in Rh-negative donors, in females with blood group III, and in males with the IV. blood group. The highest IL-8 contents in platelet lysate were also recorded in Rh-negative, group IV men and women. Platelet lysate of volunteers with the II blood group (men, Rh-negative; women, Rh-positive) contained the highest amount of RANTES. Significant differences were found between the MIP-1β levels in thrombolysate of men and women with the second A (II), and AB (IV) Rh-negative blood groups; between women of the third B (III) blood group with different Rh factors. Moreover, statistically significant differences were found in the RANTES/CCL5 chemokine values in the thrombolysate for the groups of men and women with the second A (II) [with R (+) and R (-)], and AB (IV) blood group (Rh+). Interestingly, in Rh (-) men with the first 0 (I) and second A (II) blood groups, the content of chemokine RANTES/CCL5 in the blood thrombolysate significantly exceeded similar values in the blood obtained from Rh-positive men. Conclusion: The relationship between the donors’ belonging to a particular blood group and the content of these chemokines is not yet clear. Future studies with deep bioinformatics analysis will reveal the unclear interrelations between these indicators.
- 28 September 2025
- Published by Russian Society of Immunology in Russian Journal of Immunology
- Vol. 28 (4) , 931-938
Open AccessContent of RANTES, IL-8 and MIP-1β chemokines in platelet lysates obtained from donor blood
Growth supplements obtained from animal sera have a rather variable range of a specific growth factor contents and are subject to potential contamination. Moreover, the growth supplements obtained from animal raw materials contain a composition of proteins, vitamins and microelements necessary for full-fledged cell growth, and one may overcome these drawbacks by replacing them with a product obtained from human donor blood. Platelet lysate contains biologically active molecules derived from endogenous granules of these blood elements. Concentration of distinct biocomponents in the resulting product is variable, depending not only on gender and blood group, but also on other, as yet unidentified individual characteristics. The aim of this study was to examine the content of some chemokines, in particular, RANTES, MIP-1β and IL-8, in platelet lysates obtained from healthy donors. The highest concentrations of MIP-1β cytokine were noted in Rh-negative donors, in females with blood group III, and in males with the IV. blood group. The highest IL-8 contents in platelet lysate were also recorded in Rh-negative, group IV men and women. Platelet lysate of volunteers with the II blood group (men, Rh-negative; women, Rh-positive) contained the highest amount of RANTES. Significant differences were found between the MIP-1β levels in thrombolysate of men and women with the second A (II), and AB (IV) Rh-negative blood groups; between women of the third B (III) blood group with different Rh factors. Moreover, statistically significant differences were found in the RANTES/CCL5 chemokine values in the thrombolysate for the groups of men and women with the second A (II) [with R (+) and R (-)], and AB (IV) blood group (Rh+). Interestingly, in Rh (-) men with the first 0 (I) and second A (II) blood groups, the content of chemokine RANTES/CCL5 in the blood thrombolysate significantly exceeded similar values in the blood obtained from Rh-positive men. Conclusion: The relationship between the donors’ belonging to a particular blood group and the content of these chemokines is not yet clear. Future studies with deep bioinformatics analysis will reveal the unclear interrelations between these indicators.
- 1 January 2025
- Published by Bulletin of the Ural Medical Academie Science in Journal of Ural Medical Academic Science
- Vol. 22 (3)
MANIFESTATION OF CHRONIC INFLAMMATORY COMPONENTS IN METABOLIC SYNDROME USING THE EXAMPLE OF CHANGES IN THE PROINFLAMMATORY ACTIVITY OF MONOCYTES/MACROPHAGES IN AN EXPERIMENTAL CELL MODEL
Metabolic syndrome (MS) is one of the most common and socially significant problems of the 21st century. Its progression contributes to the onset and development of a number of serious comorbidities, such as insulin resistance/diabetes mellitus, liver and kidney damage, cardiovascular pathologies. Such a broad profile of comorbidities is due to the development of systemic chronic inflammation. The most important cells involved in this process are tissue-resident macrophages. We hypothesise that the negative effects of proinflammatory factors in MS in general may also affect the monocyte-macrophage component of the immune system. The aim of the study is to identify differences in monocyte/macrophage activity in individuals with MS compared to conditionally healthy donors. Materials and methods. Monocyte/macrophage cultures obtained from the whole blood of individuals with MS using the immunomagnetic separation method were used for the study. An experimental in vitro model was developed to determine the sensitivity of immune cells to a proinflammatory stimulus (LPS) as assessed by the production of the cytokines MCP-1, TNF-α, IL-1β, IL-6, IL-8 and IL-10 by the cells. Results and conclusions. A decrease in the activity of peripheral blood monocytes is observed in MS; they show a decreased basal secretion of cytokines, which may indicate a suppression of their cytokine-producing activity due to a high concentration of proinflammatory factors in the circulation in MS. For IL-6 and IL-10, but not for other cytokines studied, an additional increase in LPS-induced secretion by monocytes in MS patients was demonstrated, which could be a consequence of both the «enrichment» of the monocyte subpopulation in the peripheral blood with «intermediate» and «non-classical» monocytes and the potential suppressor activity of IL-6. The correct formation of target groups plays an important role in the in vitro investigation of monocyte/macrophage activity in patients with MS. In particular, grouping MS patients by obesity level (BMI) could be more informative than the option based on grouping data by MS components.
- 1 January 2025
- Published by Bulletin of the Ural Medical Academie Science in Journal of Ural Medical Academic Science
- Vol. 22 (3)
MANIFESTATION OF CHRONIC INFLAMMATORY COMPONENTS IN METABOLIC SYNDROME USING THE EXAMPLE OF CHANGES IN THE PROINFLAMMATORY ACTIVITY OF MONOCYTES/MACROPHAGES IN AN EXPERIMENTAL CELL MODEL
Metabolic syndrome (MS) is one of the most common and socially significant problems of the 21st century. Its progression contributes to the onset and development of a number of serious comorbidities, such as insulin resistance/diabetes mellitus, liver and kidney damage, cardiovascular pathologies. Such a broad profile of comorbidities is due to the development of systemic chronic inflammation. The most important cells involved in this process are tissue-resident macrophages. We hypothesise that the negative effects of proinflammatory factors in MS in general may also affect the monocyte-macrophage component of the immune system. The aim of the study is to identify differences in monocyte/macrophage activity in individuals with MS compared to conditionally healthy donors. Materials and methods. Monocyte/macrophage cultures obtained from the whole blood of individuals with MS using the immunomagnetic separation method were used for the study. An experimental in vitro model was developed to determine the sensitivity of immune cells to a proinflammatory stimulus (LPS) as assessed by the production of the cytokines MCP-1, TNF-α, IL-1β, IL-6, IL-8 and IL-10 by the cells. Results and conclusions. A decrease in the activity of peripheral blood monocytes is observed in MS; they show a decreased basal secretion of cytokines, which may indicate a suppression of their cytokine-producing activity due to a high concentration of proinflammatory factors in the circulation in MS. For IL-6 and IL-10, but not for other cytokines studied, an additional increase in LPS-induced secretion by monocytes in MS patients was demonstrated, which could be a consequence of both the «enrichment» of the monocyte subpopulation in the peripheral blood with «intermediate» and «non-classical» monocytes and the potential suppressor activity of IL-6. The correct formation of target groups plays an important role in the in vitro investigation of monocyte/macrophage activity in patients with MS. In particular, grouping MS patients by obesity level (BMI) could be more informative than the option based on grouping data by MS components.
- 1 October 2021
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 27 (37) , 3924-3938
The Pathogenic Subpopulation of Th17 Cells in Obesity
Obesity is a metabolic disease characterized by a chronic subclinical inflammatory response associated with an imbalance/dysregulation of cellular homeostasis in response to excessive nutrient intake and accumulation. CD4+ T-lymphocytes form different populations, Th1, Th2, Th9, Th17, Th22, and Treg cells, which have phenotypic and functional differences. Despite the active study of Th17 cells in severe disorders, their role in metabolic disorders, particularly in obesity, is not well understood. Th17 lymphocytes, depending on the microenvironment, can form pathogenic and nonpathogenic subpopulations. Systemic inflammation induces the reprogramming of the transcriptome of normal Th17 cells formed in epithelial tissues, which acquire new properties. A zone of overlapping states exists between IL-17A-producing cells, which does not allow a clear boundary between non-pathogenic Th17 and pathogenic Th17 lymphocytes. We assume that in obesity, the pool of inflammatory pathogenic Th17 cells with cytotoxic potential is a fraction of terminally differentiated memory lymphocytes which is responsible for developing autoimmune reactions.
- 1 October 2021
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 27 (37) , 3924-3938
The Pathogenic Subpopulation of Th17 Cells in Obesity
Obesity is a metabolic disease characterized by a chronic subclinical inflammatory response associated with an imbalance/dysregulation of cellular homeostasis in response to excessive nutrient intake and accumulation. CD4+ T-lymphocytes form different populations, Th1, Th2, Th9, Th17, Th22, and Treg cells, which have phenotypic and functional differences. Despite the active study of Th17 cells in severe disorders, their role in metabolic disorders, particularly in obesity, is not well understood. Th17 lymphocytes, depending on the microenvironment, can form pathogenic and nonpathogenic subpopulations. Systemic inflammation induces the reprogramming of the transcriptome of normal Th17 cells formed in epithelial tissues, which acquire new properties. A zone of overlapping states exists between IL-17A-producing cells, which does not allow a clear boundary between non-pathogenic Th17 and pathogenic Th17 lymphocytes. We assume that in obesity, the pool of inflammatory pathogenic Th17 cells with cytotoxic potential is a fraction of terminally differentiated memory lymphocytes which is responsible for developing autoimmune reactions.
- 28 December 2018
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 19 (11) , 902-909
Erythropoietin Directly Affects Human Macrophage Functionality
We studied direct effects of erythropoietin (Epo) on functional properties of human monocytes/macrophages (Mc/Mphs) in vitro. Cells expressing CD14 marker (a co-receptor for bacterial LPS) were isolated from human peripheral blood mononuclear cells (PBMCs) by positive magnetic separation. We showed that Epo treatment reduce the percentages of CD14+ cells, CD124 (alpha subunit of IL-4 receptor)+ cells and CD197 (CCR7) + cells in non-activated Mph cultures without affecting the levels of CD16 (low-affinity Fc-receptor)+ and CD119 (interferon-γ (IFN-γ) receptor)+ cells. Epo also markedly reduced percentages of CD197+ cells in LPS-activated Mc/Mphs, without significantly affecting the expression of all other molecular markers studied. In addition, Epo caused moderate up-regulation of interleukin-1β (IL-1β) and IL-6 production in resting Mc/Mph cultures, as compared to the down-regulation of IL-1β and IL-6 production in LPS-activated cells. No Epo-mediated effects on tumor necrosis factor-α (TNF-α) and IL-10 production were observed. Our data suggests that Epo effects on Mph functionality are largely dependent on the baseline activation status of these cells, and that Epo exerts no distinct direct effects on the particular Mph polarization pathway. This data contributes to better understanding of mechanisms underlying Mph-mediated, anti-inflammatory effects of Epo, which are an important immunotherapeutic target in autoimmune diseases.
- 28 December 2018
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 19 (11) , 902-909
Erythropoietin Directly Affects Human Macrophage Functionality
We studied direct effects of erythropoietin (Epo) on functional properties of human monocytes/macrophages (Mc/Mphs) in vitro. Cells expressing CD14 marker (a co-receptor for bacterial LPS) were isolated from human peripheral blood mononuclear cells (PBMCs) by positive magnetic separation. We showed that Epo treatment reduce the percentages of CD14+ cells, CD124 (alpha subunit of IL-4 receptor)+ cells and CD197 (CCR7) + cells in non-activated Mph cultures without affecting the levels of CD16 (low-affinity Fc-receptor)+ and CD119 (interferon-γ (IFN-γ) receptor)+ cells. Epo also markedly reduced percentages of CD197+ cells in LPS-activated Mc/Mphs, without significantly affecting the expression of all other molecular markers studied. In addition, Epo caused moderate up-regulation of interleukin-1β (IL-1β) and IL-6 production in resting Mc/Mph cultures, as compared to the down-regulation of IL-1β and IL-6 production in LPS-activated cells. No Epo-mediated effects on tumor necrosis factor-α (TNF-α) and IL-10 production were observed. Our data suggests that Epo effects on Mph functionality are largely dependent on the baseline activation status of these cells, and that Epo exerts no distinct direct effects on the particular Mph polarization pathway. This data contributes to better understanding of mechanisms underlying Mph-mediated, anti-inflammatory effects of Epo, which are an important immunotherapeutic target in autoimmune diseases.
- 15 March 2018
- Published by ECO-Vector LLC in Genes & Cells
- Vol. 13 (1) , 65-69
Interleukin-8 is able to promote pro-inflammatory activity of human monocytes (macrophages)
- 15 March 2018
- Published by ECO-Vector LLC in Genes & Cells
- Vol. 13 (1) , 65-69
Interleukin-8 is able to promote pro-inflammatory activity of human monocytes (macrophages)
- 1 March 2018
- Published by Elsevier in International Immunopharmacology
- Vol. 56, 217-221
Interleukin-8 favors pro-inflammatory activity of human monocytes/macrophages
- 1 March 2018
- Published by Elsevier in International Immunopharmacology
- Vol. 56, 217-221
Interleukin-8 favors pro-inflammatory activity of human monocytes/macrophages
- 1 September 2017
- Published by Elsevier in International Immunopharmacology
- Vol. 50, 178-185
Direct effects of interleukin-8 on growth and functional activity of T lymphocytes
- 1 September 2017
- Published by Elsevier in International Immunopharmacology
- Vol. 50, 178-185
Direct effects of interleukin-8 on growth and functional activity of T lymphocytes
- Open Access
- 1 January 2017
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 19 (5) , 529-536
A ROLE FOR INTERLEUKIN 8 IN DIRECT REGULATION OF T CELL FUNCTIONAL ACTIVITY
CD3+Т-лимфоциты выделяли из мононуклеарных клеток нормальных доноров методом позитивной магнитной сепарации. Показано, что продукция интерлейкина-8 (interleukin-8, IL-8) Т-клетками возрастала в ответ на их активацию частицами, конъюгированными с антителами к молекулам CD3, СD28 и СD2. Исходно рецептор к IL-8 (CXCR1, CD181) экспрессировался на 13,3% Т-лимфоцитов. Активация Т-лимфоцитов приводила к заметному увеличению содержания CD181+ клеток среди CD4+ наивных Т-лимфоцитов, CD4+ терминально-дифференцированных Т-эффекторов и снижению их числа среди CD4+ клеток эффекторной памяти. Активацию Т-лимфоцитов оценивали по экспрессии молекулы CD25 (рецептор к IL-2). Установлено, что IL-8 в диапазоне концентраций 0,01-10,0 нг/мл способен снижать активацию как CD4-, так и CD4+Т-клеток эффекторной памяти и терминально-дифференцированных Т-эффекторов, не оказывая при этом существенного влияния на активацию наивных Т-лимфоцитов и Т-клеток центральной памяти. IL-8 усиливал продукцию активированными Т-клетками IL-2, снижал продукцию IL-10 и существенно не влиял на секрецию IFNγ и IL-4. Полученные данные указывают на значимость IL-8 в прямой регуляции адаптивных Т-клеточных реакций.
- 1 January 2017
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 19 (5) , 529-536
Open AccessA ROLE FOR INTERLEUKIN 8 IN DIRECT REGULATION OF T CELL FUNCTIONAL ACTIVITY
CD3+Т-лимфоциты выделяли из мононуклеарных клеток нормальных доноров методом позитивной магнитной сепарации. Показано, что продукция интерлейкина-8 (interleukin-8, IL-8) Т-клетками возрастала в ответ на их активацию частицами, конъюгированными с антителами к молекулам CD3, СD28 и СD2. Исходно рецептор к IL-8 (CXCR1, CD181) экспрессировался на 13,3% Т-лимфоцитов. Активация Т-лимфоцитов приводила к заметному увеличению содержания CD181+ клеток среди CD4+ наивных Т-лимфоцитов, CD4+ терминально-дифференцированных Т-эффекторов и снижению их числа среди CD4+ клеток эффекторной памяти. Активацию Т-лимфоцитов оценивали по экспрессии молекулы CD25 (рецептор к IL-2). Установлено, что IL-8 в диапазоне концентраций 0,01-10,0 нг/мл способен снижать активацию как CD4-, так и CD4+Т-клеток эффекторной памяти и терминально-дифференцированных Т-эффекторов, не оказывая при этом существенного влияния на активацию наивных Т-лимфоцитов и Т-клеток центральной памяти. IL-8 усиливал продукцию активированными Т-клетками IL-2, снижал продукцию IL-10 и существенно не влиял на секрецию IFNγ и IL-4. Полученные данные указывают на значимость IL-8 в прямой регуляции адаптивных Т-клеточных реакций.
- 1 October 2016
- Published by Tech Science Press in European Cytokine Network
- Vol. 27 (4) , 102-107
Direct effects of interleukin-7 on the function of human T cells in vitro
СD3+ T lymphocytes were isolated by positive magnetic separation from the peripheral blood of healthy donors. In the absence of any additional activating stimuli, interleukin-7 (IL-7) was shown to augment the levels of T cells expressing CD25 activation marker both in СD4-positive and in CD4-negative effector memory (CD45RA-CD197-) T cell subsets, as well as in terminally differentiated (CD45RA+CD197-) Т cells, without significantly affecting the activation status of naive (CD45RA+CD197+) and central memory (CD45RA-CD197+) T cells. In addition, IL-7 noticeably enhanced the production of IL-2, interferon-γ (IFN-γ), and IL-10, but not IL-4, in T cells. The direct effects of IL-7 on T cell activation induced in vitro by MACSiBead™ particles coated with CD2, CD3, and CD28 antibodies (Abs) were also investigated. Upon cell activation, IL-7 significantly augmented the levels of CD25+ T cells in naive (CD45RA+CD197+), central memory (CD45RA-CD197+), and effector memory (CD45RA-CD197-) T-cell compartments. In addition, IL-7 facilitated activation of СD4- (but not CD4+) terminally differentiated effector (CD45RA+CD197-) Т cells. Finally, IL-7 was found to upregulate the production of IL-2, IFN-γ, IL-4, and IL-10 by activated T cells. In conclusion, we speculate that IL-7 is capable of enhancing functional T cell activity without causing significant functional inbalance between various T cell subsets.
- 1 October 2016
- Published by Tech Science Press in European Cytokine Network
- Vol. 27 (4) , 102-107
Direct effects of interleukin-7 on the function of human T cells in vitro
СD3+ T lymphocytes were isolated by positive magnetic separation from the peripheral blood of healthy donors. In the absence of any additional activating stimuli, interleukin-7 (IL-7) was shown to augment the levels of T cells expressing CD25 activation marker both in СD4-positive and in CD4-negative effector memory (CD45RA-CD197-) T cell subsets, as well as in terminally differentiated (CD45RA+CD197-) Т cells, without significantly affecting the activation status of naive (CD45RA+CD197+) and central memory (CD45RA-CD197+) T cells. In addition, IL-7 noticeably enhanced the production of IL-2, interferon-γ (IFN-γ), and IL-10, but not IL-4, in T cells. The direct effects of IL-7 on T cell activation induced in vitro by MACSiBead™ particles coated with CD2, CD3, and CD28 antibodies (Abs) were also investigated. Upon cell activation, IL-7 significantly augmented the levels of CD25+ T cells in naive (CD45RA+CD197+), central memory (CD45RA-CD197+), and effector memory (CD45RA-CD197-) T-cell compartments. In addition, IL-7 facilitated activation of СD4- (but not CD4+) terminally differentiated effector (CD45RA+CD197-) Т cells. Finally, IL-7 was found to upregulate the production of IL-2, IFN-γ, IL-4, and IL-10 by activated T cells. In conclusion, we speculate that IL-7 is capable of enhancing functional T cell activity without causing significant functional inbalance between various T cell subsets.